TickerGuard
Buy Day today: Good (67) Broad market participation · no major macro event

ResMed Inc (RMD)

Healthcare Medical Instruments & Supplies
215.20 $
+2.0% vs. previous close
Closing price · As of: 3. Aug 2026

Who owns ResMed Inc (RMD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 70.0%.

Ownership Structure

Institutional ownership
70.0%
Insiders
0.5%
Float
99.4%
Short % of float
10.8%
Shares Outstanding
145Mio.

Largest Shareholders

Institutions

Institutions RMD
Name Stake (%) Shares Change (%) Date
BlackRock Inc 8.34 12,094,023 -2.1 03/31/2026
Vanguard Capital Management, LLC 6.53 9,466,416 +0.0 03/31/2026
Vanguard Portfolio Management, LLC 5.42 7,863,922 +0.0 03/31/2026
State Street Corp 4.58 6,643,168 +0.3 03/31/2026
Bank of New York Mellon Corp 3.40 4,925,386 +0.7 03/31/2026
Geode Capital Management, LLC 3.00 4,352,873 +1.2 03/31/2026
Morgan Stanley - Brokerage Accounts 1.85 2,686,821 -7.1 03/31/2026

Funds

Funds RMD
Name Stake (%) Shares Change (%) Date
Vanguard Morn Total Stk Mkt Idx Investor 3.18 4,606,127 -0.7 06/30/2026
Vanguard 500 Index Investor 2.60 3,767,218 -1.2 06/30/2026
Vanguard Morn Mid Cap Index Instl 2.17 3,143,479 -0.5 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
7. Jul 2026 Farrell Michael J. Chairman and CEO Sell 4,991 218.55 1,090,771
7. Jul 2026 Farrell Michael J. Chairman and CEO Other 4,991 146.34 730,383

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?